No business profile yet.
Size Odyssey Therapeutics (ODTX) is a United States Health Care company (Biotechnology) with a market value of $912M, the 2287th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.98 on 18 Nov 2026.
Performance Over six months the shares gained 11.9%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 33.5% over the last twelve months (peer median +2.0%); the operating margin is -5,415.2% (peer median -21.2%).
Valuation It trades at 204.9× enterprise value to sales against a peer median of 5.6× (2nd most expensive of 18).
Capital Return on invested capital runs 193.5 points below its cost of capital (19.7% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | $2.98M | $4.47M | $1.04M | $0 |
| Revenue growth | — | -33% | +331% | — | — |
| Gross profit | n/a | -$1.94M | -$721,000 | -$3.87M | -$2.76M |
| EBITDA | n/a | -$156M | -$130M | -$129M | -$120M |
| Net income | n/a | -$149M | -$129M | -$126M | -$125M |
| Free cash flow | n/a | -$131M | -$118M | -$118M | -$113M |
| Capital expenditure | n/a | $1.23M | $764,000 | $5.06M | $13.0M |
| Total debt | $23.5M | $27.1M | $31.0M | $34.4M | $40.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ODTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.1% | -9.0% | 7th highest of 21 |
| 6-month return | +11.9% | -17.5% | 4th highest of 21 |
| Distance from 52-week high | -34.7% | -41.8% | 5th highest of 21 |
| Revenue growth (TTM) | -33.5% | +2.0% | 2nd lowest of 17 |
| Operating margin | -5,415.2% | -21.2% | 2nd lowest of 18 |
| EV / Sales | 204.9× | 5.6× | 2nd most expensive of 18 |
| ROIC minus cost of capital | -193.5 pp | -8.9 pp | lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 2.9× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | 8.0× | 4.8% | -32.3% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |